Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03948360
Recruitment Status : Recruiting
First Posted : May 13, 2019
Last Update Posted : May 13, 2019
Sponsor:
Information provided by (Responsible Party):
Rogers Sciences Inc.

Brief Summary:
The primary purpose of this first-in-human, early feasibility study is to assess safety and feasibility of the Low-Irradiance Monochromatic Biostimulation (LIMB) System as a phototherapeutic intervention for the management of acute burn wounds. The prototype LIMB device will be evaluated for the occurrence of adverse events (treatment-related or otherwise) of the LIMB System, a portable, wearable, light-emitting system developed by Rogers Sciences, Inc. (RSI). The device will be administered in the small feasibility pilot to confirm design, usability and operating specifications that will inform procedures and endpoints of a subsequent large, multicenter clinical trial.

Condition or disease Intervention/treatment Phase
Burn Wound Device: Low-Irradiance Monochromatic Biostimulation (LIMB) Device Other: Standard of Care Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: The study model is sequential. Arm I will consist of the first 3 participants, with each participant receiving LIMB phototherapy over standard of care (SOC). The subsequent participants will comprise Arm II, with each participant to receive only LIMB phototherapy without standard of care. Dose modifications of the phototherapy can be made in Arm II, and will be determined based on any treatment-related adverse events observed in Arm I. Up to 12 participants in total will be enrolled.
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: A First-In-Human Pilot Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds
Actual Study Start Date : September 7, 2017
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: LIMB Phototherapy with SOC
Arm I: The first 3 participants enrolled will receive standard of care therapy under the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device.
Device: Low-Irradiance Monochromatic Biostimulation (LIMB) Device
The LIMB System is a portable and wearable phototherapeutic system that consists of a Light Patch and Power Pack. The Power Pack delivers power to the Light Patch, which attaches to the participant and emits blue spectrum (405nm low-irradiance) light. The Light Patch contains an array of thin optical arrays that evenly illuminate the surface. The Power Pack is powered by a Lithium Thionyl Chloride (Li-SOCI2) battery.

Other: Standard of Care
Standard of care therapy as defined for this clinical trial is standard gauze dressing soaked in Sulfamylon (mafenide acetate) solution.

Experimental: LIMB Phototherapy without SOC
Arm II: The subsequent participants will receive only the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device without standard of care.
Device: Low-Irradiance Monochromatic Biostimulation (LIMB) Device
The LIMB System is a portable and wearable phototherapeutic system that consists of a Light Patch and Power Pack. The Power Pack delivers power to the Light Patch, which attaches to the participant and emits blue spectrum (405nm low-irradiance) light. The Light Patch contains an array of thin optical arrays that evenly illuminate the surface. The Power Pack is powered by a Lithium Thionyl Chloride (Li-SOCI2) battery.




Primary Outcome Measures :
  1. Occurrence of Adverse Events from LIMB Phototherapy as Assessed by CTCAE v4.0 [ Time Frame: up to 7 days ]
    To evaluate the occurrence of adverse events (treatment-related or otherwise) from LIMB phototherapy from the time of device application up to 7 days. Reporting consistent with CTCAE v4.0. Duration of LIMB phototherapy can be shortened per discretion of treating Investigator.


Secondary Outcome Measures :
  1. Change in Bioburden assessed through Wound Culture [ Time Frame: up to 7 days ]
    To evaluate the effect of LIMB phototherapy on microbial bioburden. Wound culture specimens are collected at each daily dressing change to measure the change in microbial bioburden when compared to baseline.


Other Outcome Measures:
  1. Change in Pain as Assessed by Checklist Pain Behavior Scale [ Time Frame: up to 7 days ]
    To evaluate the change in participant's pain score during LIMB phototherapy treatment. Pain assessments taken daily at dressing change.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients receiving care at Shriners Hospitals for Children-Boston for a skin tissue injury.
  • Patients who have at least one wound with exposed area sufficient, in the Investigator's opinion, to receive LIMB therapy.
  • Willing and able to adhere to daily LIMB therapy protocol.

Exclusion Criteria:

  • Patients deemed not medically stable by the treating Investigator.
  • Patients with clinical signs and symptoms of systemic infection at baseline.
  • Patients with burn wounds limited to their head and genitalia.
  • Patients who, in the opinion of the Investigator, will not require daily dressing changes.
  • Patients receiving photosensitizing agents that result in cutaneous phototoxicity prior to enrollment. Patients who have received one or more of the following photosensitizers cannot be enrolled into the study: photofrin, amiodarone, chloropromazine, fluoroquinolone antibiotics, thiazide diuretics, quinine, demethylchlortetracycline, psoralens, nalidixic acid, tetracycline, naproxen.
  • Patients currently enrolled or participating in another investigational device, drug or biological trial within 30 days of the Screening Visit.
  • Patients currently receiving any bandages or devices containing silver compounds.
  • Patients on a ventilator, who have fluid resuscitation or are in any terminal condition.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03948360


Locations
Layout table for location information
United States, Massachusetts
Shriners Hospitals for Children-Boston Recruiting
Boston, Massachusetts, United States, 02114
Contact: Robert L Sheridan, MD    617-722-3000    rsheridan@partners.org   
Sponsors and Collaborators
Rogers Sciences Inc.
Investigators
Layout table for investigator information
Principal Investigator: Robert L. Sheridan, MD Shriners Hospitals for Children-Boston

Layout table for additonal information
Responsible Party: Rogers Sciences Inc.
ClinicalTrials.gov Identifier: NCT03948360    
Other Study ID Numbers: BOS1705
First Posted: May 13, 2019    Key Record Dates
Last Update Posted: May 13, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Rogers Sciences Inc.:
acute burn, thermal injury, wound, phototherapy, wound healing, antimicrobial
Additional relevant MeSH terms:
Layout table for MeSH terms
Burns
Wounds and Injuries